Your browser doesn't support javascript.
loading
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Kelley, Robin Kate; Rimassa, Lorenza; Cheng, Ann-Lii; Kaseb, Ahmed; Qin, Shukui; Zhu, Andrew X; Chan, Stephen L; Melkadze, Tamar; Sukeepaisarnjaroen, Wattana; Breder, Valery; Verset, Gontran; Gane, Edward; Borbath, Ivan; Rangel, Jose David Gomez; Ryoo, Baek-Yeol; Makharadze, Tamta; Merle, Philippe; Benzaghou, Fawzi; Banerjee, Kamalika; Hazra, Saswati; Fawcett, Jonathan; Yau, Thomas.
Afiliación
  • Kelley RK; Department of Medicine (Hematology/Oncology), UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. Electronic address: katie.kelley@ucsf.edu.
  • Rimassa L; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Cheng AL; National Taiwan University Cancer Center, Taipei, Taiwan; National Taiwan University Hospital, Taipei, Taiwan.
  • Kaseb A; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Qin S; Cancer Center of Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, China.
  • Zhu AX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA; Jiahui International Cancer Center, Jiahui Health, Shanghai, China.
  • Chan SL; State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir Yue-Kong Pao Center for Cancer, The Chinese University of Hong Kong, Hong Kong.
  • Melkadze T; Academician Fridon Todua Medical Center-Research Institute of Clinical Medicine Tbilisi, Georgia.
  • Sukeepaisarnjaroen W; Department of Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand.
  • Breder V; FSBSI N N Blokhin Russian Cancer Research Center, Moscow, Russia.
  • Verset G; Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
  • Gane E; New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; Department of Medicine, University of Auckland, Auckland, New Zealand.
  • Borbath I; Department of Hepato-Gastroenterology, Cliniques Universitaires St Luc, Brussels, Belgium.
  • Rangel JDG; Department of Medical Oncology, Centro Oncologico de Veracruz, CLIMERS, Veracruz, Mexico.
  • Ryoo BY; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Makharadze T; High Technology Hospital Medcenter, Batumi, Adjara, Georgia.
  • Merle P; Hepatology Unit, Hôpital de la Croix-Rousse, Groupement Hospitalier Lyon Nord, Lyon, France.
  • Benzaghou F; Ipsen Bioscience, Cambridge, MA, USA.
  • Banerjee K; Exelixis, Alameda, CA, USA.
  • Hazra S; Exelixis, Alameda, CA, USA.
  • Fawcett J; Exelixis, Alameda, CA, USA.
  • Yau T; Department of Medicine, University of Hong Kong, Hong Kong, China.
Lancet Oncol ; 23(8): 995-1008, 2022 08.
Article en En | MEDLINE | ID: mdl-35798016
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido